GlobeNewswire Inc.··Oxford BiotherapeuticsOxford BioTherapeutics Lands Major Deal with Bristol Myers Squibb on Cancer Immunotherapy
Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.
BMYCELGroncologyAntibody-Drug Conjugates